Hoverman JR. Rethinking clinical oncology drug research in an era of value-based cancer care: A role for chemotherapy pathways.
Cancer Med 2020;
9:5306-5311. [PMID:
32524722 PMCID:
PMC7404003 DOI:
10.1002/cam4.3193]
[Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2020] [Revised: 05/15/2020] [Accepted: 05/15/2020] [Indexed: 01/05/2023] Open
Abstract
The United States spends nearly 1/5th of its GDP on healthcare. Yet, to achieve value-based care, the Economist describes the US healthcare system as handicapped by multiple, disparate silos that prevent the organization and sharing of data. This paper explores the current state of clinical oncology drug research and its relationship to value-based cancer care. Clinical Chemotherapy Pathways are proposed as a unifying structure to bring together disparate sources of data to increase value.
Collapse